Many brain tumor patients do not receive adequate end-of-life care
(Massachusetts General Hospital) While more than 60 percent of patients with the brain tumors called malignant gliomas enroll in hospice services, almost a quarter of them do so within a week of death, probably too late for patients and family members to benefit from hospice care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news
UCLA grant program funds interdisciplinary brain cancer research
When a neurosurgeon looks at a glioblastoma, an aggressive form of brain cancer, she sees a dark mass bullying its way through the brain. When an oncologist talks to a patient with glioblastoma, he tempers expectations, talking in months rather than years. When a molecular biologist thinks about glioblastoma, she thinks about the tumor ’s sweet tooth — the sugar it consumes to fuel its frenetic growth. And when you put all these people together — you get a plan to fight cancer.Armed with new research tools and a grant from the David Geffen School of Medicine ’s newSeed Grant Program, a team of UCLA researchers, inc...
Source: UCLA Newsroom: Health Sciences - December 18, 2017 Category: Universities & Medical Training Source Type: news
Novel mechanism that protects from glioblastoma identified
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) A group of researchers at the Spanish National Cancer Research Centre (CNIO) have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression. Moreover, reconstitution of RanBP6 in a mouse xenograft model leads to reduction in tumor growth. Authors state that these findings might have " important clinical implications " . (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 18, 2017 Category: Biology Source Type: news
25% of high-grade glioma patients alive 3 years post trial
Patients with recurrent high-grade glioma were treated by the University of Minnesota Medical School. Median survival was 14.4 months, compared with the typical 8 months. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2017 Category: Consumer Health News Source Type: news
Onalespib could be an effective treatment for glioblastoma, preclinical studies show
This study showed that the targeted drug onalespib reduced the expression of cell-survival proteins such as AKT and endothelial growth factor receptor in glioma cell lines and glioma stem cells from patient tumors. This, in turn, reduced the survival, proliferation, invasion and migration of the cells. In animal models of glioblastoma the agent crossed the blood-brain barrier and showed effectiveness as a single agent and greater effectiveness in combination with temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2017 Category: International Medicine & Public Health Source Type: news
25% of high-grade glioma patients live 3 years after trail
Patients with recurrent high-grade glioma were treated by the University of Minnesota Medical School. Median survival was 14.4 months, compared with the typical 8 months. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news
Gene Therapy May Fight Brain Cancer's Return
FRIDAY, Oct. 27, 2017 -- A new form of gene therapy shows promise in battling recurrent brain cancer.
The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer.
Three years after the gene therapy treatment, more... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 27, 2017 Category: General Medicine Source Type: news
An experimental model might shed new light on the development of brain cancer in children
(DZNE - German Center for Neurodegenerative Diseases) Researchers of the German Center for Neurodegenerative Diseases (DZNE) present in the journal Cancer Cell a novel laboratory model that replicates key hallmarks of pediatric high-grade glioma. Results might pave the way for a better understanding of processes, relevant for both cancer and neurodegeneration. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 27, 2017 Category: International Medicine & Public Health Source Type: news
Cancer trial led by University of Minnesota Medical School's Dr. Clark Chen shows promise
(University of Minnesota Medical School) New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 27, 2017 Category: Cancer & Oncology Source Type: news
Biology of childhood brain tumor subtypes offers clues to precision treatments
(Children's Hospital of Philadelphia) Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood cancer. By shedding light on subtle distinctions in tumor biology, these findings offer clues to designing more effective anticancer treatments to precisely target tumors in individual patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news
Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells
(University Hospitals Cleveland Medical Center) Study demonstrates, for the first time, that glioblastoma (GBM) is driven by two distinct subsets of cancer stem cells. Moreover, each subtype of glioma stem cells is driven by distinct transcriptional programs for growth and treatment resistance. The subsets also responded better to combination treatment in the mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 9, 2017 Category: Cancer & Oncology Source Type: news
Papers of note in Nature 549 (7673)
This week’s articles highlight the role of vitamin C in hematopoietic cells; a source of maternal inflammation that contributes to neurodevelopmental defects; the blocking of a niche factor that promotes the growth of gliomas; and a protein that influences DNA repair pathway choice. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 3, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news
Brainlab wins FDA nod for Elements Spine, Cranial SRS radiosurgery planning software
Brainlab said today it won FDA clearance for its Elements Spine SRS and Elements Cranial SRS radiosurgery surgical planning software applications.
The Munich, Germany-based company said that the Elements Cranial SRS is designed to allow physicians to create radiosurgery plans in less than 15 minutes, supporting plans for numerous cranial indications including arteriovenous malformations, pituitary adenoma, vestibular schwannoma, glioma, meningioma and large brain metastases.
“We are highly impressed with the dosimetric results and the speed of plan optimization. We ran a few plan comparisons between our other plannin...
Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Radiosurgery Regulatory/Compliance Software / IT Brainlab Source Type: news
Stanford researchers halt brain cancer growth with absence of protein
Research at Stanford University suggests the growth of specific brain tumors -- high-grade gliomas -- can be stopped by cutting off access to a signaling molecule. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 21, 2017 Category: Consumer Health News Source Type: news
Researchers hit the brakes on lethal brain cancers in mice
(NIH/National Institute of Neurological Disorders and Stroke) New research conducted in mice provides evidence that highly lethal brain tumors, called high-grade gliomas, stop growing when deprived of a specific molecule naturally produced when brain cells fire. The experiments, led by a group of scientists from Stanford University, Palo Alto, California, suggest that targeting a protein called neuroligin-3 may prove beneficial in patients with these diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news
